# Signals Article: Putative Target Q9NS00 for IgA Nephropathy
Background
IgA nephropathy, also known as Berger's disease, is a kidney disorder characterized by the deposition of the immunoglobulin A (IgA) in the glomeruli, leading to inflammation and, eventually, kidney damage. It is one of the most common forms of glomerulonephritis worldwide and can progress to chronic kidney disease or end-stage renal failure. Despite its prevalence, the pathogenesis of IgA nephropathy is not fully understood, and treatment options are limited. Identifying novel molecular targets could provide new therapeutic opportunities.
Data-mining rationale
In a recent reanalysis effort, UniProt entry Q9NS00 was identified as a putative target for IgA nephropathy. This candidate emerged from cross-referencing UniProt's reviewed human entries with expression-profiling studies in the NCBI GEO database, specifically datasets GDS:200261305, GDS:200072326, GDS:200151457, GDS:200151454, and GDS:200125818. Although Q9NS00 is present in these studies, it has not been associated with any registered Phase 1 or higher clinical programs, suggesting its potential as an unexplored target.
Why prior analyses may have missed this
Many of the GEO datasets containing Q9NS00 predate modern empirical-Bayes statistical methods, such as limma, which are crucial for accurate differential expression analysis. The absence of proper multiple-testing correction in earlier analyses may have led to the underestimation of Q9NS00's potential as a target for IgA nephropathy. Additionally, the lack of integration with pathway and tissue-specific databases may have obscured its relevance.
Reasoning for further validation
To fully assess the potential of Q9NS00 as a target for IgA nephropathy, several steps are recommended. Re-analyzing the matched GEO datasets using limma with Benjamini-Hochberg FDR correction will provide a more accurate picture of differential expression. Validation of top differentially-expressed genes by qPCR in an independent cohort is essential to confirm findings. Checking tissue specificity in GTEx and the Human Protein Atlas will help determine the target's relevance in the context of IgA nephropathy. Running pathway analyses using STRING or OmniPath will provide insights into the biological context of Q9NS00. If validated, assessing the druggability of Q9NS00 via DGIdb and ChEMBL will be crucial for potential therapeutic development.